Free Trial

Graybug Vision (GRAY) Competitors

Graybug Vision logo
$2.37 -0.12 (-4.64%)
As of 08/13/2025

GRAY vs. NNVC, TAOX, IBIO, OBSV, AEON, MTNB, AEZS, NRBO, VAXX, and SPRB

Should you be buying Graybug Vision stock or one of its competitors? The main competitors of Graybug Vision include NanoViricides (NNVC), Synaptogenix (TAOX), iBio (IBIO), ObsEva (OBSV), AEON Biopharma (AEON), Matinas Biopharma (MTNB), Aeterna Zentaris (AEZS), NeuroBo Pharmaceuticals (NRBO), Vaxxinity (VAXX), and Spruce Biosciences (SPRB).

Graybug Vision vs. Its Competitors

Graybug Vision (NASDAQ:GRAY) and NanoViricides (NYSE:NNVC) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, media sentiment, earnings, profitability, risk and dividends.

Graybug Vision's return on equity of -77.61% beat NanoViricides' return on equity.

Company Net Margins Return on Equity Return on Assets
Graybug VisionN/A -77.61% -71.34%
NanoViricides N/A -87.90%-78.69%

Graybug Vision has a beta of 1.2, suggesting that its share price is 20% more volatile than the S&P 500. Comparatively, NanoViricides has a beta of 0.96, suggesting that its share price is 4% less volatile than the S&P 500.

In the previous week, Graybug Vision had 1 more articles in the media than NanoViricides. MarketBeat recorded 1 mentions for Graybug Vision and 0 mentions for NanoViricides. Graybug Vision's average media sentiment score of 1.10 beat NanoViricides' score of 0.00 indicating that Graybug Vision is being referred to more favorably in the media.

Company Overall Sentiment
Graybug Vision Positive
NanoViricides Neutral

49.9% of Graybug Vision shares are held by institutional investors. Comparatively, 10.3% of NanoViricides shares are held by institutional investors. 7.9% of Graybug Vision shares are held by company insiders. Comparatively, 4.6% of NanoViricides shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

NanoViricides is trading at a lower price-to-earnings ratio than Graybug Vision, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Graybug VisionN/AN/A-$35.60M-$24.23-0.10
NanoViricidesN/AN/A-$8.29M-$0.70-2.14

Summary

Graybug Vision beats NanoViricides on 8 of the 10 factors compared between the two stocks.

Get Graybug Vision News Delivered to You Automatically

Sign up to receive the latest news and ratings for GRAY and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GRAY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

GRAY vs. The Competition

MetricGraybug VisionPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$8.64M$851.84M$5.66B$9.82B
Dividend YieldN/A4.84%3.79%4.07%
P/E Ratio-1.371.1930.5825.12
Price / SalesN/A26.45462.42114.82
Price / CashN/A19.5637.4059.05
Price / Book1.426.589.096.18
Net Income-$35.60M-$4.98M$3.25B$264.89M
7 Day Performance-13.69%2.96%7.32%4.18%
1 Month Performance15.37%2.02%5.41%1.99%
1 Year Performance-43.53%13.30%30.66%24.22%

Graybug Vision Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
GRAY
Graybug Vision
N/A$2.37
-4.6%
N/A-42.3%$8.64MN/A-1.3727News Coverage
Positive News
Gap Up
High Trading Volume
NNVC
NanoViricides
0.313 of 5 stars
$1.54
flat
N/A-21.9%$24.75MN/A-2.1420
TAOX
Synaptogenix
N/A$8.34
+12.9%
N/AN/A$10.27MN/A-0.834Positive News
Earnings Report
Analyst Downgrade
IBIO
iBio
1.1947 of 5 stars
$0.57
-2.3%
$5.00
+772.4%
-59.9%$9.47M$375K0.00100
OBSV
ObsEva
N/AN/AN/AN/A$7.94MN/A0.0050
AEON
AEON Biopharma
3.4462 of 5 stars
$0.69
+5.0%
$360.00
+52,134.5%
-99.0%$7.79MN/A3.835Gap Down
MTNB
Matinas Biopharma
1.5289 of 5 stars
$1.48
-7.5%
N/AN/A$7.53MN/A-0.3130Short Interest ↓
Gap Up
AEZS
Aeterna Zentaris
N/A$3.58
-0.4%
N/A-46.2%$6.42M$2.37M-0.2420
NRBO
NeuroBo Pharmaceuticals
N/A$0.64
+1.3%
N/A-83.6%$5.50MN/A0.0010Gap Up
VAXX
Vaxxinity
N/A$0.04
+42,900.0%
N/A+107.7%$5.45MN/A-0.1090Gap Up
SPRB
Spruce Biosciences
2.0491 of 5 stars
$9.15
-8.4%
$131.25
+1,334.4%
-73.5%$5.14M$4.91M-9.7320News Coverage
Negative News
Short Interest ↑

Related Companies and Tools


This page (NASDAQ:GRAY) was last updated on 8/16/2025 by MarketBeat.com Staff
From Our Partners